



Vivimed

Date: February 7th, 2019

To
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam


Sub: Clarification/ Information -SALE OF 50% STAKE IN ITS 50:50 JV TO STRIDES –reg.

Ref: Your mail dated: 01.02.2019

With reference to above, we hereby attached required clarification / information in relation to our press release dated: 29.01.2019.

This is for your information and records.

Thanking you,
For VIVIMED LABS LIMITED


(K. YUGANDHAR)
COMPANY SECRETARY



Vivimed Labs Limited.

CIN: L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka - 585 403, India.

T +91 (0) 8482-232045, F +91 (0) 8482-232436

Email: contact@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

North End, Road No. 2

Banjara Hills, Hyderabad,

Telangana - 500 034, India.

GSTIN: 36AAACV6060A1ZQ

T +91(0) 40-6608-6608, F +91(0) 40-6608-6699

**Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sale of 50% stake in its 50:50 JV to Strides

a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; (Vivimed Life Sciences Private Limited)	FY 18 Turnover – INR 23.78 crores (1.99%) FY 18 Net worth – INR 75.12 crores (13.24%)
b) Date on which the business transfer agreement for sale has been entered;	Not Applicable
c) The expected date of completion of sale/disposal	Q4 FY19
d) Consideration to be received from such sale/disposal;	INR 73.33 crores
e) Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ group companies. If yes, details thereof;	Strides Pharma Science Limited proposes to acquire balance 50% stake in Vivimed Life Sciences Private Limited. Post such acquisition, Vivimed Life Sciences will be a wholly owned subsidiary of Strides Pharma Science Limited. The buyers do not belong to Promoters and Promoter group companies.
f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No
g) Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	NA

Gugandhar



**Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sale of 50% stake in its 50:50 JV to Strides

a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; (Strides Vivimed Pte. Ltd., Singapore)	FY 18 Turnover – USD 18,782 (0.012%) FY 18 Net worth – USD 2630000 (3.32%)
b) Date on which the business transfer agreement for sale has been entered;	Not Applicable
c) The expected date of completion of sale/disposal	Q4 FY19
d) Consideration to be received from such sale/disposal;	USD 240,000
e) Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ group companies. If yes, details thereof;	Strides Pharma Global Pte. Limited, Singapore, a step-down wholly owned subsidiary of Strides Pharma Science Limited proposes to acquire balance 50% stake in Strides Vivimed Pte. Ltd., Singapore. Post such acquisition, Strides Vivimed Pte. Ltd., Singapore will be a wholly owned subsidiary of Strides Pharma Global Pte. Limited, Singapore. The buyers do not belong to Promoters and Promoter group companies.
f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No
g) Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	NA

